Patents/Assignees

H. Lundbeck A/S

62 patents in portfolio

US12331123utility2025
Agent, Uses and Methods for Treatment
0 cites
US12319710utility2025
Catecholamine Prodrugs for Use in the Treatment of Parkinson's Diseases
0 cites
US12258305utility2025
Alcohol Derivatives as Kv7 Potassium Channel Openers
0 cites
US12258340utility2025
Pyrazole MAGL Inhibitors
0 cites
US12226428utility2025
Catecholamine Prodrugs for Use in the Treatment of Parkinson's Disease
0 cites
US12215144utility2025
Acute Treatment and Rapid Treatment of Headache Using Anti-cgrp Antibodies
0 cites
US12215145utility2025
Treatment of Headache Using Anti-cgrp Antibodies
0 cites
US12162936utility2024
Methods of Treatment with Anti-pacap Antibodies
0 cites
US12152029utility2024
Crystalline Forms of a MAGL Inhibitor
0 cites
US12129289utility2024
Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof
0 cites
US12122821utility2024
Regulation of Glucose Metabolism Using Anti-cgrp Antibodies
0 cites
US12116355utility2024
Deuterated 1-piperazino-3-phenyl Indanes for Treatment of Schizophrenia
0 cites
US12077578utility2024
Compositions and Methods for Treating Synucleinopathies
0 cites
US12077581utility2024
Anti-pacap Antibodies and Uses Thereof
0 cites
US12077794utility2024
Temperature Shift for High Yield Expression of Polypeptides in Yeast and Other Transformed Cells
0 cites
US12071416utility2024
Prodrugs of 4-( (1R, 3s)-6-chloro-3-phenyl-2, 3-dihydro-1h-inden-1-yl)-1,2, 2-trimethylpiperazine and 4-( (1R, 3s)-6-chloro-3-(phenyl-d5)-2, 3-dihydro-1h-inden-1-yl)-2, 2-dimethyl-1 (methyl-d3) Piperazine
0 cites
US11993588utility2024
Crystalline Forms of a MAGL Inhibitor
0 cites
US11993612utility2024
LRRK2 Inhibitors
0 cites
US11958865utility2024
Leucine-rich Repeat Kinase 2 (LRRK2) Inhibitors
0 cites
US11938185utility2024
Treatment of Headache, Migraine And/or Photophobia Conditions Using Humanized Anti-pacap Antibodies
0 cites

← PreviousPage 2 of 4Next →